Earnings Call · Q2 FY2024·2024-08-15

Q2 24EPS -8.70%·Rev n/aQ1 24EPS -34.55%·Rev n/aQ4 23EPS +37.50%·Rev n/aQ3 23EPS +39.13%·Rev n/a⚠ consensus missing

NRX Pharmaceuticals, Inc. NRXP

Matthew Duffy — Chief Business Officer

Dr. Jonathan Javitt — Founder and Chief Scientist

Stephen Willard — CEO

Richard Narido — Chief Financial Officer

−6.5%1d on move date−8.2% vs SPY3d−6.8%5d+2.2%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NRXP calls or request research access.

More NRXP calls Browse calls Request research access